Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2013 | 03-2013 | 12-2012 | 09-2012 | 06-2012 | |
| Sales | 3,745,776 | 3,538,989 | 3,653,377 | 3,335,945 | 3,364,070 |
| Cost of Goods | 631,771 | 639,154 | 549,307 | 585,829 | 591,667 |
| Gross Profit | 3,114,005 | 2,899,835 | 3,104,069 | 2,750,116 | 2,772,403 |
| Operating Expenses | 1,610,684 | 1,560,759 | 1,781,322 | 1,429,006 | 1,450,632 |
| Operating Income | 1,504,092 | 1,339,230 | 1,323,055 | 1,321,938 | 1,322,438 |
| Interest Expense | 46,778 | 19,127 | 24,335 | 70,602 | 147,917 |
| Other Income | 63,597 | 55,787 | 2,373 | -14,288 | 25,229 |
| Pre-tax Income | 1,520,911 | 1,375,890 | 1,301,093 | 1,237,048 | 1,199,750 |
| Income Tax | 341,114 | 316,478 | 296,319 | 284,425 | 275,962 |
| Net Income Continuous | 1,179,797 | 1,059,412 | 1,004,775 | 952,623 | 923,789 |
| Net Income | $1,179,797 | $1,059,412 | $1,004,775 | $952,623 | $923,789 |
| EPS Basic Total Ops | 0.22 | 0.20 | 0.19 | 0.17 | 0.17 |
| EPS Basic Continuous Ops | 0.22 | 0.20 | 0.18 | 0.17 | 0.17 |
| EPS Diluted Total Ops | 0.22 | 0.19 | 0.18 | 0.17 | 0.17 |
| EPS Diluted Continuous Ops | 0.22 | 0.19 | 0.18 | 0.17 | 0.17 |
| EBITDA(a) | $1,504,092 | $1,339,230 | $1,323,055 | $1,321,938 | $1,322,438 |